Eagle Asset Management Inc. Has $18.80 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Eagle Asset Management Inc. reduced its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 37.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 176,249 shares of the company's stock after selling 106,102 shares during the quarter. Eagle Asset Management Inc. owned about 0.14% of Vaxcyte worth $18,800,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of PCVX. Darwin Global Management Ltd. increased its stake in shares of Vaxcyte by 374.3% in the 1st quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company's stock valued at $187,907,000 after buying an additional 2,170,845 shares during the period. Vanguard Group Inc. increased its position in Vaxcyte by 15.2% in the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company's stock worth $665,152,000 after purchasing an additional 1,284,883 shares during the period. Janus Henderson Group PLC raised its holdings in Vaxcyte by 9.9% during the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company's stock worth $524,117,000 after purchasing an additional 692,492 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Vaxcyte by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company's stock worth $216,966,000 after buying an additional 498,359 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Vaxcyte by 47.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company's stock worth $148,075,000 after buying an additional 419,600 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. Leerink Partners lifted their target price on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a report on Tuesday, September 3rd. Jefferies Financial Group upped their price objective on Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. BTIG Research raised their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Bank of America upped their price target on Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. Finally, Needham & Company LLC restated a "buy" rating and set a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, November 6th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $147.50.

Vaxcyte Stock Up 0.2 %

Shares of Vaxcyte stock traded up $0.15 on Friday, hitting $88.54. The company had a trading volume of 1,614,295 shares, compared to its average volume of 1,610,634. The stock has a 50-day moving average of $107.89 and a 200-day moving average of $89.26. Vaxcyte, Inc. has a twelve month low of $48.24 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period last year, the company posted ($0.91) earnings per share. On average, equities research analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other Vaxcyte news, CEO Grant Pickering sold 2,366 shares of the company's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total transaction of $245,803.74. Following the sale, the chief executive officer now directly owns 137,398 shares of the company's stock, valued at approximately $14,274,278.22. This represents a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Elvia Cowan sold 5,000 shares of Vaxcyte stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total transaction of $538,350.00. Following the completion of the transaction, the senior vice president now directly owns 12,723 shares of the company's stock, valued at approximately $1,369,885.41. This trade represents a 28.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 102,464 shares of company stock valued at $11,455,576 in the last quarter. 3.10% of the stock is currently owned by insiders.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.